2038 Stock Overview
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, develops, produces, and markets genetic engineering and related drugs in the People’s Republic of China and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Beijing SL Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥8.31 |
52 Week High | CN¥16.09 |
52 Week Low | CN¥7.05 |
Beta | 0.35 |
1 Month Change | -8.48% |
3 Month Change | -2.69% |
1 Year Change | -5.35% |
3 Year Change | -18.29% |
5 Year Change | -50.30% |
Change since IPO | 698.15% |
Recent News & Updates
Shareholder Returns
2038 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 0.1% | -3.8% | -0.4% |
1Y | -5.4% | -26.7% | -16.2% |
Return vs Industry: 002038 exceeded the CN Biotechs industry which returned -26.7% over the past year.
Return vs Market: 002038 exceeded the CN Market which returned -16.2% over the past year.
Price Volatility
2038 volatility | |
---|---|
2038 Average Weekly Movement | 6.2% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 8.9% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 002038 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002038's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 757 | Mingbo Xu | www.slpharm.com.cn |
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, develops, produces, and markets genetic engineering and related drugs in the People’s Republic of China and internationally. The company’s finished formulations includes temozolomide; arsenic trioxide; lenalidomide capsules; docetaxel; paclitaxel; recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; liraglutide; insulin aspart 30; insulin aspart 50; insulin aspart; recombinant human follitropin(rh-fsh); ciclosporin; mycophenolate mofetil dispersible; voriconazole; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; rivaroxaban; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin; paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients.
Beijing SL Pharmaceutical Co., Ltd. Fundamentals Summary
2038 fundamental statistics | |
---|---|
Market cap | CN¥8.54b |
Earnings (TTM) | CN¥314.02m |
Revenue (TTM) | CN¥999.82m |
27.2x
P/E Ratio8.5x
P/S RatioIs 2038 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2038 income statement (TTM) | |
---|---|
Revenue | CN¥999.82m |
Cost of Revenue | CN¥177.51m |
Gross Profit | CN¥822.32m |
Other Expenses | CN¥508.29m |
Earnings | CN¥314.02m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 24, 2024
Earnings per share (EPS) | 0.31 |
Gross Margin | 82.25% |
Net Profit Margin | 31.41% |
Debt/Equity Ratio | 0% |
How did 2038 perform over the long term?
See historical performance and comparison